Clinical trial
A One-Month Bleeding-Model Clinical Study
Name
2020112
Description
The objective of the study is to evaluate the gingivitis control benefit of an established stannous fluoride containing toothpaste relative to a negative control dentifrice.
Trial arms
Trial start
2020-10-19
Estimated PCD
2020-11-20
Trial end
2020-11-20
Status
Completed
Treatment
0.454% stannous fluoride
Brush two times daily
Arms:
Positive Control
0.76% sodium monofluorophosphate
Brush two times daily
Arms:
Negative Control
0.454% stannous fluoride AM and 0.76% sodium monofluorophosphate PM
Brush two times daily
Arms:
Experimental Control
Size
90
Primary endpoint
Löe-Silness Gingivitis Evaluation
Baseline
Löe-Silness Gingivitis Evaluation
Week 4
Eligibility criteria
Inclusion Criteria:
* Be at least 18 years of age;
* Provide written informed consent prior to participation and be given a signed copy of the informed consent form;
* Be in general good health as determined by the Investigator based on a review of the health history/update for participation in the trial;
* Have at least 20 gradable teeth;
* Have established gingivitis with ≥10 % bleeding sites;
* Agree to return for scheduled visits and follow the study procedures;
* Agree to refrain from use of any non-study oral hygiene products for the duration of the study;
* Agree to delay any elective dentistry, including dental prophylaxis, until the completion of the study.
Exclusion Criteria:
* Having taken medications (antibiotic, anti-inflammatory, or anti-coagulant) which could alter gingival bleeding within 4 weeks of the Baseline Visit;
* Having any oral conditions that could interfere with study compliance and/or examination procedures, such as widespread caries, soft or hard tissue tumor of the oral cavity, or advanced periodontal disease;
* Having known hypersensitivity to the test products;
* Having removable oral appliances;
* Having fixed facial or lingual orthodontic appliances;
* Self-reported pregnancy or lactation;
* Having any diseases or condition that might interfere with the safe participation in the study;
* Having an inability to undergo study procedures.
Protocol
{'studyType': 'INTERVENTIONAL', 'phases': ['NA'], 'designInfo': {'allocation': 'RANDOMIZED', 'interventionModel': 'PARALLEL', 'primaryPurpose': 'TREATMENT', 'maskingInfo': {'masking': 'DOUBLE', 'whoMasked': ['PARTICIPANT', 'OUTCOMES_ASSESSOR']}}, 'enrollmentInfo': {'count': 90, 'type': 'ACTUAL'}}
Updated at
2023-06-23
1 organization
3 products
1 indication
Organization
Procter and GambleProduct
Stannous FluorideIndication
GingivitisProduct
Sodium Monofluorophosphate